Schizophrenia is rarely a single-episode illness. In fact, 8 out of 10 patients will experience a relapse of symptoms after initial treatment. So how can we help reduce the frequency of relapse—and even non-adherence—among our patients with schizophrenia? To find out, Dr. Andrew Wilner is joined by Dr. Jose Rubio, psychiatrist at Long Island Jewish Medical Center and Assistant Professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, to talk about the use of long-acting injectable (LAI) antipsychotics for schizophrenia treatment.